Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
French rapper Gims placed under investigation for 'aggravated money laundering' - 2Disney's latest short film 'Versa' tackles a difficult subject: Pregnancy loss. It's resonating with viewers.
- 3Flash flooding causes highways to close to and from Eilat
- 4Most normal matter in the universe isn't found in planets, stars or galaxies – an astronomer explains where it's distributed
- 5The Most Paramount Crossroads in Olympic History
- 37 Things Just Individuals Experiencing childhood during the 80s Will Comprehend
- Must-See Attractions in Australia
- Energy agency chief warns of 'black April' for oil supplies
- Exploring ways to reduce the impact of space junk on Earth
- The new queen of country music has no scandals and no gimmicks — and just broke a record set by Taylor Swift
- The Delight of Perusing: Book Proposals for Each Class
- Flu season is just beginning, but doctors are already on high alert
- Germany sees third consecutive diesel price record after rule change
- Artemis II astronauts are more than halfway to the moon as they seek to break Apollo 13's record
